P2X7 on Mouse T Cells: One Channel, Many Functions
Björn Rissiek, Friedrich Haag, Olivier Boyer, Friedrich Koch-Nolte, Sahil Adriouch

To cite this version:
Björn Rissiek, Friedrich Haag, Olivier Boyer, Friedrich Koch-Nolte, Sahil Adriouch. P2X7 on Mouse T Cells: One Channel, Many Functions. Frontiers in Immunology, Frontiers, 2015, 6, pp.204. 10.1016/j.jchromb.2016.05.001 . hal-02376237

HAL Id: hal-02376237
https://hal-normandie-univ.archives-ouvertes.fr/hal-02376237
Submitted on 22 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
P2X7 on mouse T cells: one channel, many functions

Björn Rissiek 1,2,*, Friedrich Haag 1, Olivier Boyer 3,4,5, Friedrich Koch-Nolte 1 and Sahil Adriouch 3,4,6

1 Institute of Immunology, University Medical Center, Hamburg, Germany, 2 Department of Neurology, University Medical Center, Hamburg, Germany. 3 U905, INSERM, Rouen, France. 4 Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, Rouen, France. 5 Department of Immunology, Rouen University Hospital, Rouen, France.

The P2X7 receptor is an adenosine triphosphate (ATP)-gated cation channel that is expressed by several cells of the immune system. P2X7 is best known for its proinflammatory role in promoting inflammasome formation and release of mature interleukin (IL)-1β by innate immune cells. Mounting evidence indicates that P2X7 is also an important regulatory receptor of murine and human T cell functions. Murine T cells express a sensitive splice variant of P2X7 that can be activated either by non-covalent binding of ATP or, in the presence of nicotinamide adenine dinucleotide, by its covalent ADP-ribosylation catalyzed by the ecto-ADP-ribosyltransferase ARTC2.2. Prolonged activation of P2X7 by either one of these pathways triggers the induction of T cell death. Conversely, lower concentrations of ATP can activate P2X7 to enhance T cell proliferation and production of IL-2. In this review, we will highlight the molecular and cellular consequences of P2X7 activation on mouse T cells and its versatile role in T cell homeostasis and activation. Further, we will discuss important differences in the function of P2X7 on human and murine T cells.

Keywords: P2X7, P2RX7, ATP, T cells, purinergic signaling

Mechanisms Leading to Activation of P2X7 by Extracellular ATP or NAD+ on Mouse T Cells

The family of ionotropic P2X receptors comprises seven members that are able to form trimeric ion channels reactive to extracellular adenosine triphosphate (ATP). In the context of the immune system, P2X7 is best known for its role in promoting inflammasome formation and release of the proinflammatory interleukin 1β (IL-1β) from innate immune cells such as macrophages and monocytes after exposure to lipopolysaccharide and ATP (1). Further, P2X7 has also been identified as an important regulator of mouse T cell functions. P2X7 triggered by extracellular ATP induces the formation of a non-selective cation channel, resulting in the influx of calcium and sodium ions as well as the efflux of potassium. Interestingly, P2X7 can also be triggered via an ATP-independent pathway that has been discovered and characterized on mouse T cells. The mechanism involves the ecto-ADP-ribosyltransferase ARTC2.2 which, in the presence of its substrate nicotinamide adenine dinucleotide (NAD+), catalyzes the ARTC2.2-dependent ADP-ribosylation of P2X7 at an arginine residue at position 125 at the edge of the ATP-binding pocket in the extracellular domain of the protein (Figure 1A) (2, 3). This covalent posttranslational modification occurs even at 4°C, however gating of P2X7 is triggered only at 37°C. Since NAD+ is released during cell preparation, alterations of T cell phenotype and function due to NAD+-dependent ADP-ribosylation of P2X7 can easily be evidenced on freshly harvested T cells extracted from lymphoid organs following their re-incubation.
A brief exposition to relatively low concentrations of extracellular ribosylation provides a long-lasting activation signal, even after activation of human T cells via the generation of cyclic ADP-ribose (cADPR) that can cause the release of Ca\(^{2+}\) from intracellular ryanodine-sensitive stores (12, 13). Additionally, the activity of these enzymes participates in the maintenance of low extracellular ATP or NAD\(^{+}\) concentrations in biological fluids. Under steady-state conditions, their concentrations in the serum have been estimated in the submicromolar range (14, 15). Therefore, activation of P2X7 by ATP or NAD\(^{+}\) is limited to situations where intracellular pools of nucleotides are released in substantial amounts. Interestingly, ATP has been demonstrated to be released in the tumor microenvironment in concentrations that are fully compatible with the in vivo direct activation of P2X7 at the surface of innate immune cells and tumor-infiltrating T cells (16, 17). Whether NAD\(^{+}\) can also be released in this situation is presently not known, but NAD\(^{+}\) has been demonstrated to be released within inflammatory sites and to affect the phenotype and survival of T cells located in the proximal draining lymph nodes via the ARTC2.2/P2X7 pathway (18).

**Molecular and Cellular Consequences of P2X7 Activation on Mouse T Cells**

Activation of P2X7 on T cells by extracellular ATP or following NAD\(^{+}\)-dependent ADP-ribosylation induces changes in cell volume and composition of the plasma membrane. T cells respond to ATP stimulation with rapid sequential shrinkage and swelling and externalization of phosphatidylserine (PS) onto the outer leaflet of the plasma membrane (Figure 1C) (19, 20). Analyses of thymocytes revealed that PS externalization is related to the influx of both, calcium and sodium ions, inhibiting aminophospholipid translocases responsible for maintaining PS at the inner leaflet of the plasma membrane, and simultaneously activating scramblases which catalyze the bidirectional transbilayer movement of PS (21–23). Externalization of PS is regarded as an early indicator of the induction of apoptosis. Prolonged activation of P2X7 indeed triggers T cell death which can be visualized by staining with DNA-binding dyes such as propidium iodide following loss of membrane integrity (4). Interestingly, PS exposure after ATP stimulation is reversible if the ATP is removed within the first 30 min of exposure (24). Conversely, PS exposure following ADP-ribosylation of P2X7 is not reversed by removing the ARTC2 substrate NAD\(^{+}\) (2).

Another hallmark of P2X7 activation is the formation of membrane pores permeable to molecules up to a molecular weight of 900 Da. Pore formation has been functionally linked to the long intracellular C-terminus region of P2X7 (25). However, whether P2X7 itself directly mediates pore formation by channel dilation or whether other P2X7-associated proteins such as pannexin 1 form the pores is still a matter of debate. Interestingly, inhibition of pannexin-1 significantly reduced ATP-induced mouse T cell death (26). This suggests that drastic elevation of intracellular Ca\(^{2+}\), either through P2X7 itself or via other associated non-selective pore-forming proteins, may represent an essential common event triggered in the early phase leading to cell death.
recently published study identified the phospholipid scramblase anoctamin 6 (ANO6), another non-selective cation channel, as a new key player in the formation of membrane pores following P2X7 activation on macrophages (27). Whether ANO6 is also involved in P2X7-mediated pore formation in T cells needs to be further investigated.

P2X7 activation is associated with a rapid change in T cell surface phenotype. The mechanism involves the activation of the membrane-associated metalloproteases ADAM10 and ADAM17 that catalyze the shedding of the ectodomains of various cell surface proteins such as CD62L (28), CD27 (29), and IL-6R (30) (Figure 1B). Hence, on the cellular level, activation of P2X7 on T cells results in the triggering of multiple signaling pathways that affect cell morphology, phenotype, and viability. In the following sections, we will discuss the impact of P2X7-mediated cell death on T cell function and homeostasis.

**Allelic and Splice Variants Affect the Functionality of P2X7**

In the mouse, single nucleotide polymorphisms (SNP) and alternative splicing result in the expression of different P2X7 variants (1, 31–35). An allelic variant of P2X7 located in the long C-terminal cytosolic tail was discovered in widely used C57BL/6 laboratory mice. The 451L variant found in this strain affects the function of the receptor when expressed by HEK cells as compared to the P451 P2X7 allelic variant found in the BALB/c strain. Side-by-side comparison of T cells from both strains concordantly showed impaired functional responses of the 451L variant to P2X7 stimulation leading to the conclusion that the P451L SNP affects the functionality of P2X7 expressed by conventional mouse T cells (36). However, later analyses using anti-P2X7 antibodies suitable for flow cytometry analysis demonstrated that conventional T cells from C57BL/6 display very low cell surface expression of P2X7 which possibly accounts for their relative insensitivity to P2X7 ligands (5). The situation was further complicated by the discovery of two alternatively spliced variants termed P2X7a and P2X7k with different sensitivity to P2X7 agonists. Structurally, the P2X7k variant differs from the previously described P2X7a by 42 amino acids encompassing the terminal cytosolic tail created by disrupting the last exon coding for the long C–terminal cytoplasmic tail (41). In the other P2X7-deficient mouse, generated by GlaxoSmithKline (GSK), the lacZ gene was inserted at the beginning of exon 1 (42–44). However, two independent studies revealed that the latter mice do express a functional P2X7 receptor on T cells, whereas DCs, macrophages, and neurons were effectively deficient in P2X7 functional activity (37, 45). Later studies revealed that this is due to the preferential use of the P2X7k variant in T cells which escapes exon 1 targeted disruption (i.e., using an alternative exon 1′) in the GSK knockout strain (37, 38). This finding may be important for our understanding of the role of this receptor in vivo and may help reinterpret some contradictory results. For instance, autoimmune encephalomyelitis was found to be exacerbated in the Pfizer knockout strain, whereas it was found to be attenuated in GSK knockout strain (46, 47). Future studies using tissue-specific P2X7 disruption in lymphoid, myeloid, or oligodendrocytes cells should help clarify this issue.

**P2X7 Expression on T Cells of Different Differentiation and Maturation Stages**

P2X7 expression on mouse T cells depends on differentiation and maturation stage. Cell death can be induced in a fraction of thymocytes by extracellular ATP suggesting that P2rx7 gene expression is induced in T cells during their differentiation in the thymus (48). The precise physiological role of P2X7 on the selection of the T cell repertoire is not known but ATP has been suggested to play a role in thymocyte death by neglect and in the thymic differentiation of γδ T cells (49). Our own early studies have revealed that single positive CD4+ or CD8+ thymocytes express higher levels of surface P2X7 than less differentiated double positive cells suggesting that P2X7 expression correlates with T cell maturation. Accordingly, peripheral T cells displayed higher sensitivity to ATP and NAD+ than thymocytes (2, 50). On mature peripheral T cells, CD4+ T cells display slightly higher surface levels of P2X7 as compared to CD8+ T cells that may account in part for their higher sensitivity to extracellular ATP and NAD+. Interestingly, P2X7 surface expression also seems to be regulated by activation. Indeed, cells expressing T cell activation markers display lower P2X7 levels than their naive counterparts (18). Also, recently activated T cells display a lower level of ARTC2.2 possibly as a result of its shedding from the cell surface by metalloproteases (51). Of note, the relative expression levels of P2X7a and P2X7k variants during cell differentiation in the thymus, in mature CD4+ or CD8+ T cell lineages, or after activation are currently not...
known but may possibly regulate the sensitivity to extracellular ATP and NAD⁺.

**P2X7-Mediated Cell Death Affects the Quality of Ex Vivo Murine T Cell Preparations**

Several studies have shown that the expression levels of P2X7 and ARTC2.2 differ among T cell subsets (52, 53). Tregs and liver natural killer T cells (NKTs) exhibit a higher cell surface expression of P2X7 as compared to conventional naïve CD4⁺ T cells, and this is associated with a higher sensitivity to ATP- and NAD⁺-mediated cell death (5, 6, 54, 55). High sensitivity to extracellular NAD⁺ negatively correlates with the survival and function of ex vivo freshly prepared Tregs and liver NKTs. This has a significant impact on in vitro assays and on adoptive transfer experiments (6). NAD⁺ is released in sufficient amounts during organ collection and cell preparation to ADP-ribosylate P2X7 on a large fraction of Tregs and on the majority of liver NKTs even when cells are prepared on ice. This leads to the induction of P2X7-mediated cell death when the cells are returned to 37°C either in vitro or after their adoptive transfer into living animals (Figure 2). To overcome this detrimental effect, an ARTC2.2-antagonizing nanobody (clone s+16a) has been developed (56) and was shown to prevent ADP-ribosylation-related detrimental effects induced during ex vivo cell preparation when injected a few minutes before sacrificing the mice (Figure 2). This markedly preserved the viability, the phenotype and the function of harvested Tregs and NKTs and improved subsequent downstream applications in vitro and in vivo (6).

**P2X7-Mediated Cell Death Regulates Mouse T Cell Homeostasis In vivo**

P2X7-dependent cell death plays an important role in the homeostatic regulation of diverse T cell populations during steady state and in pathophysiological contexts. The endogenous sources of extracellular ATP and NAD⁺ remain an important question when addressing the role of P2X7 in vivo. Obviously, ATP and NAD⁺ can be passively liberated from damaged cells in traumatic situations (4). However, extracellular nucleotides can also be liberated from living cells in various situations (e.g., during cell activation, during autophagy, in conditions of shear-force stress, oxidative stress, or from transformed cells) through hemichannels such as pannexin 1 or connexin 43 and possibly through other still unknown mechanisms (57, 58). In a proof-of-principle study, we previously showed that NAD⁺ is released at inflammatory sites and even can gain access to the local draining lymph nodes (18). This led to P2X7-dependent phenotypic changes and to the depletion of a fraction of naïve T cells that were detectable in wildtype (WT) mice and, more prominently, in CD38-deficient mice, in which NAD⁺ has a longer half-life in the extracellular compartment.

Given the higher sensitivity of Tregs and NKTs to ATP- and NAD⁺-mediated cell death, the role of P2X7 in their homeostatic maintenance in vivo was studied (5, 6, 54, 55). P2X7 negatively regulates the number of peripheral Tregs and was therefore suggested to participate in their homeostasis. Indeed, P2X7-deficient mice exhibit higher numbers of Tregs in the spleen compared to their WT counterparts. Conversely, CD38-deficient mice display lower numbers of Tregs in the spleen, indirectly suggesting that

---

**FIGURE 2** P2X7-dependent alteration of T cells can be prevented by blocking the activity of ARTC2.2. Freshly prepared spleen CD4⁺ Foxp3⁺ Tregs and liver CD3⁺CD1d-tetramer⁺ NKT cells remain unaffected when kept at 4°C but rapidly shed CD27 when re-incubated at 37°C due to NAD⁺ release during cell preparation and ARTC2.2-mediated ADP-ribosylation of P2X7 (left panel). These cells also rapidly shed CD62L and expose phosphatidylserine at their cell surface (not illustrated here). Intravenous injection of an anti-ARTC2.2 blocking nanobody (s+16a) before harvesting of the organs prevents ADP-ribosylation of P2X7 during cell manipulation and P2X7-dependent CD27 shedding when cells are re-incubated at 37°C (right panel).
extracellular NAD$^+$ also regulates Treg homeostasis (5). Whether the increased number of Tregs in P2X7-deficient mice is related to ATP- and/or NAD$^+$-induced cell death needs to be further investigated. Interestingly, CD38 deficiency similarly affects the number of NKTs. This was observed in diabetes-prone NOD mice, in which CD38 deficiency was accompanied by an accelerated onset of diabetes (59). We could further show that in vivo blockade of the ARTC2.2/P2X7 pathway using an ARTC2.2-antagonistic nanobody restored normal numbers of NKT cells in these mice suggesting that extracellular NAD$^+$ indeed can influence NKT cell homeostasis (59).

The high sensitivity of Tregs and NKTs to NAD$^+$-induced P2X7-dependent cell death has been exploited to deplete these cells in vivo. Injection of NAD$^+$ into mice depleted NKT cells and protected mice from concanavalin A (ConA)-mediated autoimmune hepatitis. This was linked to a transient decrease in the number of liver NKT cells, which otherwise respond to ConA with a massive production of proinflammatory cytokines resulting in severe liver damage (55, 60). Similarly, a single intravenous injection of NAD$^+$ decreased the number of peripheral Tregs by 80%. When applied 24 h before tumor engraftment, this unleashed an effective anti-tumor immune response leading to tumor rejection (5).

The role of P2X7 in the tumor microenvironment has been investigated in two recent publications addressing tumor promotion and tumor growth in P2X7-deficient mice. In one of these studies, genetic and pharmacological inactivation of P2X7 was demonstrated to increase tumor development in a model of colitis-associated cancer (61). Interestingly, this was associated with alteration of the number and the quality of tumor-infiltrating immune cells and, notably, by the accumulation of Tregs within the colonic lesions. Their accumulation in the tumor of P2X7-deficient is compatible with their high sensitivity to P2X7-dependent cell death. In the following section, we will highlight the role of P2X7 in different physiological and pathophysiological situations (62).

In summary, current data suggest that P2X7-mediated cell death constitutes a crucial factor for the homeostatic regulation of several T cell subsets that play essential roles in the regulation of immune responses. P2X7 can therefore be viewed as an important regulator of T cell functions, notably through the induction of P2X7-dependent T cell death. Still, dependent on the level of expression of P2X7 and on the amount of available extracellular ATP and/or NAD$^+$, P2X7 may also conceivably regulate T cell activation and/or function without necessarily inducing cell death. In the following section, we will highlight the role of P2X7 as a co-stimulatory partner during the activation of T cells.

**P2X7-Mediated Autocrine Stimulation of Human and Mouse T Cells**

It has become clear that ATP can be released from living cells in different physiological and pathophysiological situations (68). For instance, hypertonic and mechanical stress induces deformation of the plasma membrane that can lead to the liberation of ATP into the extracellular milieu from many cell types. When applied to Jurkat T cells, hypertonic stress leads to the rapid release of extracellular ATP, to the augmentation of intracellular Ca$^{2+}$, to mitogen-activated protein kinase...
(MAPK) activation, and to enhanced expression of interleukin 2 (IL-2) \((69)\). Studies addressing the underlying mechanisms of ATP release identified pannexin 1 hemichannels as a critical mediator of ATP release in response to hypertonic stress \((70)\). Interestingly, TCR stimulation by itself triggered the release of ATP in a pannexin-1 dependent manner \((71, 72)\). ATP released

![Diagram of ATP release and its effects on T cells](image)

**FIGURE 3** | Modulation of human T cells phenotype, response to mitogenic stimulation, and survival by ATP and P2X7. P2X7-stimulation on the surface of human T cell may have different consequences which could hypothetically depend on the extracellular concentration of ATP, P2X7 density, expression of CD39 and other ATPases, on the nature of T cell subsets, and on their activation status. (A) High concentration of extracellular ATP have been reported to culminate, at least in vitro, in the induction of cell death possibly through the induction of massive membrane depolarization and permeabilization. (B) At lower ATP concentration and/or if cells express a low level of surface P2X7 and/or a high level of ATP-catabolizing enzymes, P2X7-activation could participate instead in T cell costimulation by enhancing the intracellular level of \(\text{Ca}^{2+}\), an universal second messenger \((76, 78)\). This may result in the stimulation of NFAT, MAPKs, and IL-2 secretion \((69, 70, 72)\), and in the activation of metalloproteases that catalyze the shedding of CD62L and of other cell surface proteins \((73)\). (C) In some studies, TCR stimulation by mitogenic activators was shown to promote ATP release through pannexin 1 favoring autocrine/paracrine T cell co-stimulation \((69, 70, 72)\). (D) TCR stimulation was also found to stimulate the translocation of pannexin 1 at the immunological synapse even if it is not actively translocated within the immunological synapse and remains instead uniformly distributed across the cell surface. This mechanism may thus serve to provide a tonic co-stimulatory signal during physiological activation of a T cell in contact with antigen-presenting cells by promoting the local release of ATP within the immunological synapse, and the local activation of P2X receptors expressed by T cell as well as by antigen-presenting cells.
during TCR stimulation activates P2X7, which sustains MAPK signaling, stimulating IL-2 expression and enhancing T cell proliferation. Further, antagonism of P2X7 during TCR activation blunted MAPK signaling and induced a transcriptional program characteristic for T cell anergy (71). The importance of this regulatory mechanism has been evaluated in a mouse model of diabetes that is based on the adoptive transfer of hemagglutinin (HA)-specific TCR-transgenic T cells into Rag2−/− mice expressing HA under control of the insulin promoter (73). Simultaneous injection of oxidized ATP (oATP) to antagonize of P2X7 in vivo prevented the onset of diabetes (71). As oATP is not an entirely specific antagonist for P2X7, the implication of other P2X receptors can also contribute to purinergic T cell stimulation. For instance, P2X1 and P2X4 were substantially inhibited by oATP (73). However, the specificity of some of these small inhibitory molecules is uncertain, precluding any definitive interpretation of the specific role of each P2X receptor on T cell stimulation. The generation of highly specific biological antagonistic nanobodies will certainly help to gain new insights on their specific roles (75).

**Discussion on the Function of P2X7 on Human and Murine T Cells**

Much work in mouse models has led to the conclusion that P2X7 regulates many aspects of mouse T cell biology. This multifaceted ATP-gated ion channel is expressed at high levels on different T cell subsets that are important for the regulation of immune responses such as Tregs, NKT cells, or Th cells. The question that may be raised is how P2X7 delivers signals that regulate such distinct events as T cell activation, proliferation, phenotype, cytokine production, and cell death (Figure 1). A possible answer might reside in the temporal and spatial regulation of the availability of extracellular purinergic ligands and on the density of P2X7 expression at the cell surface. Long-lasting whole-cell activation of P2X7 by high concentrations of ATP or NAD+ in cells expressing high levels of P2X7 might promote cell death, whereas short pulses and/or low global amounts of ATP or its restricted presence at only one side of a cell, such as would occur in the immunological synapse, might instead promote TCR-mediated activation of T cells (Figure 3). Hints in this direction have been provided by studies showing that low concentrations of ATP co-stimulate proliferation of human peripheral blood T lymphocytes (76), Jurkat cell (74) and human activated/memory CD4+ T cells (77), whereas 1 mM ATP induces T cell death (76, 77). It may be stressed here that ATP-triggered cell death of human T cells differs greatly in magnitude and kinetics as compared to mouse T cells. ATP-triggered cell death of human T cell is observed in smaller fractions of cells and only when exposed to millimolar ATP concentrations for a few days. For comparison, 1–30 μM NAD+ or 100–300 μM of ATP suffice to induce cell death of the vast majority of mouse T cells within an hour. These differences may be linked to the lower expression level of P2X7 at the surface of human T cells and to the absence of a highly potent T cell-specific P2X7 variant in humans analogous to the mouse P2X7k variant. Hence, further studies will be required to clarify the physiological roles of P2X7 in the regulation of human T cell death, homeostasis, and activation.

**Acknowledgments**

The authors would like to thank Inserm, Normandy University, Deutsche Forschungsgemeinschaft (DFG), and ERA-NET NEURON (NanoStroke) for their financial supports. DFG grants: SFB877-A5, HA2369/5 and NO310/11.

**References**

1. Bartlett R, Stokes L, Shyter R. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. *Pharmacol Rev* (2014) 66:638–75. doi:10.1124/pr.113.008003
2. Seman M, Adriouch S, Scheuphlein F, Krebs C, Freese D, Glowacki G, et al. NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. *Immunity* (2003) 19:571–82. doi:10.1016/S1074-7613(03)00266-8
3. Adriouch S, Bannas P, Schwarz N, Fliegert R, Guse AH, Seman M, et al. ADP-ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site. *FASEB J* (2007) 22:861–9. doi:10.1096/fj.07-9294com
4. Scheuplern F, Schwarz N, Adriouch S, Krebs C, Bannas P, Rissiek B, et al. NAD+ and ATP released from injured cells induce P2X7-dependent shedding of CD62L and externalization of phosphatidylserine by murine T cells. *J Immunol* (2009) 182:2898–908. doi:10.4049/jimmunol.0801711
5. Hubert S, Rissiek B, Klages K, Huelen J, Sparwasser T, Haag F, et al. Extracellular NAD+ shapes the Fsp3+ regulatory T cell compartment through the ART2–P2X7 pathway. *J Exp Med* (2010) 207:2561–8. doi:10.1084/jem.20091154
6. Rissiek B, Danquah W, Haag F, Koch-Nolte F. Technical advance: a new cell preparation strategy that greatly improves the yield of vital and functional Tregs and NKT cells. *J Leukoc Biol* (2014) 95:543–9. doi:10.1189/jlb.0713407
7. Haag F, Koch-Nolte F, Kühl M, Lorenzen S, Thiele HG. Premature stop codons inactivate the RT6 genes of the human and chimpanzee species. *J Mol Biol* (1994) 243:537–46. doi:10.1006/jmbi.1994.1680
8. Schwarz N, Fliegert R, Adriouch S, Seman M, Guse AH, Haag F, et al. Activation of the P2X7 ion channel by soluble and covalently bound ligands. *Purinergic Signal* (2009) 5:139–49. doi:10.1007/s11302-009-9135-5
9. Lévesque SA, Kukulski F, Enjojiy K, Robson SC, Sévigny J. NTPDase1 governs P2X7-dependent functions in murine macrophages. *Eur J Immunol* (2010) 40:1473–85. doi:10.1002/eji.200939741
10. Kuhny M, Hochdörfer T, Ayata CK, Idzik M, Huber M. CD39 is a negative regulator of P2X7-mediated inflammatory cell death in mast cells. *Cell Commun Signal* (2014) 12:40. doi:10.1186/s12964-014-0040-3
11. Krebs C, Adriouch S, Braasch F, Koestner W, Leiter EH, Seman M, et al. CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins. *J Immunol* (2005) 174:3298–305. doi:10.4049/jimmunol.174.6.3298
12. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med* (2007) 204:1257–65. doi:10.1084/jem.20062512
13. Magnone M, Bauer I, Poggi A, Mannino E, Sturla L, Brini M, et al. NAD+ levels control Ca2+ store replenishment and mitogen-induced increase of cytosolic Ca2+ by Cyclic ADP-ribose-dependent TRPM2 channel gating in human T lymphocytes. *J Biol Chem* (2012) 287:21067–81. doi:10.1074/jbc.M111.324269
14. Di Virgilio F, Boezaems J-M, Robson SC. Extracellular nucleotides as negative modulators of immunity. Curr Opin Pharmacol (2009) 9:507–13. doi:10.1016/j.coph.2009.06.021
15. Haag F, Adiouch S, Braß A, Jung C, Möller S, Scheuplein F, et al. Extracellular NAD and ATP: partners in immune cell modulation. Purinergic Signal (2007) 3:71–81. doi:10.1007/s11302-006-0038-7
16. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins J, Kroemer G, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 70:835–6. doi:10.1158/0008-5472.CAN-09-3566
17. Garg AD, Krysko OV, Verfallie T, Kazimarek A, Ferreira GB, Maryasel T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 31:1062–79. doi:10.1038/emboj.2011.497
18. Adiouch S, Hubert S, Pechbery S, Koch-Nolte F, Haag F, Seman M. NAD+ released during inflammation participates in T cell homeostasis by inducing ART2-mediated death of naive T cells in vivo. J Immunol (2007) 179:186–94. doi:10.4049/jimmunol.179.1.186
19. Taylor SRJ, Gonzalez-Begne M, Dewhurst S, Chimini G, Higgins CF, Melvin JE, et al. Sequential shrinkage and swelling underlie P2X7-stimulated lymphocyte phospholipid exposure and death. J Immunol (2008) 180:300–8. doi:10.4049/jimmunol.180.1.300
20. Adiouch S, Ohlrogge W, Haag F, Koch-Nolte F, Seman M. Rapid induction of naive T cell apoptosis by ecto-nicotinamide adenine dinucleotide: requirement for mono(ADP-ribosyl)transferase 2 and a downstream effector. J Biol Chem (2008) 283:21815–23. doi:10.1074/jbc.M401426200
21. Bratton DL, Fadok VA, Richter DA, Kaley JM, Guthrie LA, Henson PM. Casein kinase II phosphorylation of P2X7 receptor-dependent ATP-induced Ca2+ transients and currents in murine thymocytes: possible role in P2X7 receptor activation in thymocytes. J Biol Chem (2004) 279:32527–34. doi:10.1074/jbc.M403855200
22. Shojo KE, Sáez PJ, Harcha PA, Aguila HLS, Sáez JC. Pannexin1 channels act downstream of P2X7 receptors in ATP-induced murine T-cell death. Channels (Austin) (2014) 8:142–56. doi:10.4161/chann.28122
23. Bevers EM, Williamson PL. Phospholipid scramblase: an update. FEBS Lett (2010) 584:2724–30. doi:10.1016/j.febslet.2010.03.020
24. Mackenzie AB, Young MT, Adinolfi E, Surprenant A. Pseudoapoptosis induced by brief activation of ATP-gated P2X7 receptors. J Biol Chem (2005) 280:33968–76. doi:10.1074/jbc.M502705200
25. Becker D, Woltersdorf R, Boldt W, Schmitz S, Braum U, Schmalzing G, et al. The P2X7 carboxyl tail is a regulatory module of P2X7 receptor channel activity. J Biol Chem (2008) 283:25275–34. doi:10.1074/jbc.M803855200
26. Solle M, Labasi J, Perregaux DG, Stam E, Petruskova N, Koller BH, et al. Altered splicing of the N-terminal cytosolic and transmembrane domains of P2X7 on T cells drives T cell lineage choice and shapes peripheral γδ T cell response. J Immunol (2010) 185:584–92. doi:10.4049/jimmunol.0900120
27. Hong S, Schwarz N, Braß A, Seman M, Haag F, Koch-Nolte F, et al. Differential regulation of P2X7 receptor activation by extracellular nicotinamide adenine dinucleotide and ecto-ADP-ribosyltransferases in murine macrophages and T cells. J Immunol (2009) 182:578–92. doi:10.4049/jimmunol.0900120
28. Ke HZ, Qi H, Weiema AF, Zhang Q, Panupinthu N, Crawford DT, et al. Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol (2003) 17:1356–67. doi:10.1212/jne.2003.0021
29. Chessel IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain (2005) 114:386–96. doi:10.1016/j.pain.2005.01.002
30. Sim JA, Young MT, Sung H-Y, North RA, Surprenant A. Reanalysis of P2X7 receptor expression in rodent brain. J Neurosci (2004) 24:4307–14. doi:10.1523/JNEUROSCI.1469-04.2004
31. Taylor SRJ, Gonzalez-Begne M, Sojka DK, Richardson JC, Shearwood DA, Harrison SM, et al. Lympocytes from P2X7-deficient mice exhibit enhanced P2X7 responses. J Leukoc Biol (2009) 85:978–86. doi:10.1189/jlb.0408251
32. Sharp AJ, Polak PE, Simonini V, Lin SX, Richardson JC, Bongarzone ER, et al. P2X7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroimmunol (2008) 5:33. doi:10.1186/1742-2049-5-33
33. Chen L, Brosnan C. Exacerbation of experimental autoimmune encephalomyelitis in P2X7R−/− mice: evidence for loss of apoptotic activity in lymphocytes. J Immunol (2006) 176:3115–26. doi:10.4049/jimmunol.176.3.3115
34. Freedman BD, Liu QH, Gaulton G, Kotlikoff MI, Hescheler J, Fleischmann BK. ATP-evoked Ca2+ transients and currents in murine thymocytes: possible role for P2X2 receptors in death by necroptosis. Eur J Immunol (1999) 29:1635–46. doi:10.1002/1660-0112(199909)29:5<1635::AID-EJIMM1463.3.0.CO;2-2
35. Frascolló M, Marcandalli J, Schenk U, Grassi F. Purinergic P2X7 receptor drives T cell lineage choice and shapes peripheral γδ T cells. J Immunol (2012) 189:174–80. doi:10.4049/jimmunol.1101582
36. Kahl S, Nissen M, Girisch R, Duffy T, Leiter EH, Haag F, et al. Metalloprotease-mediated shedding of enzymatically active mouse ecto-ADP-ribosyltransferase ART2.2 upon ‘T cell activation. J Immunol (2000) 165:4463–9. doi:10.4049/jimmunol.165.8.4463
37. Asow F, Dennert G. P2X7 receptor expression levels determine lethal effects of a purine based danger signal in T lymphocytes. Cell Immunol (2006) 243:58–65. doi:10.1016/j.cellimm.2006.12.003
Rissiek et al.

53. Rissiek B, Haag F, Boyer O, Koch-Nolte F, Adiouch S. ADP-ribosylation of P2X7: a matter of life and death for regulatory T cells and natural killer T cells. *Curr Top Microbiol Immunol* (2014) 384:107–26. doi:10.1007/82_2014_420

54. Aswad F, Kawamura H, Dennert G. High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. *J Immunol* (2005) 175:3075–83. doi:10.4049/jimmunol.175.5.3075

55. Kawamura H, Aswad F, Minagawa M, Govindarajan S, Dennert G. P2X7 receptors regulate NKT cells in autoimmune hepatitis. *J Immunol* (2006) 176:2152–60. doi:10.4049/jimmunol.176.4.2152

56. Koch-Nolte F, Reeyelt J, Schüssow B, Schwarz N, Scheuplein F, Rothenburg S, et al. Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. *FASEB J* (2007) 21:3490–8. doi:10.1096/fj.07–8661com

57. Bao L, Locovei S, Dahl G. Pannexin membrane channels are mechanosensitive conduits for ATP. *FEBS Lett* (2004) 572:65–8. doi:10.1016/j.febslet.2004.07.009

58. Bruzzzone S, Guida L, Zocchi E, Franco L, De Flora A. Connexin 43 hemicannels mediate Ca2+-regulated transmembrane NAD+ fluxes in intact cells. *FASEB J* (2001) 15:10–2. doi:10.1096/fj.00–05660je

59. Scheuplein F, Rissiek B, Driver JP, Chen Y-G, Koch-Nolte F, Serreze DV. A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. *J Autoimmun* (2010) 34:145–54. doi:10.1016/j.jaut.2009.08.012

60. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. *Proc Natl Acad Sci U S A* (2000) 97:5498–503. doi:10.1073/pnas.040566997

61. Hofman P, Cherflis-Veijni J, Bazin M, Ile M, Juvel T, Heubetere X, et al. Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer. *Cancer Res* (2015) 75:835–45. doi:10.1158/0008-5472.CAN–14–1778

62. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. *Nat Med* (2009) 15:1170–8. doi:10.1038/nm.2028

63. Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, et al. Accelerated tumor progression in mice lacking the ATP receptor P2X7. *Cancer Res* (2015) 75:635–44. doi:10.1158/0008-5472.CAN–14–1259

64. Heiss K, Jänner N, Mähnls B, Schumacher V, Koch-Nolte F, Haag F, et al. High sensitivity of intestinal CD8+ T cells to nucleotides indicates P2X7 as a regulator for intestinal T cell responses. *J Immunol* (2008) 181:3861–9. doi:10.4049/jimmunol.181.6.3861

65. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song S-Y. Retinoic acid imprints gut-homing specificity on T cells. *Immunology* (2004) 201:527–38. doi:10.1061/j.immuni.2004.08.011

66. Coombes JL, Siddiqui KRR, Arancibia-Carcamo CV, Hall J, Sun C-M, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. *J Exp Med* (2007) 204:1757–64. doi:10.1084/jem.2007590

67. Proietti M, Cornavarchio V, Rezzonico Jost T, Romagnani A, Falti CE, Perruzza L, et al. ATP-gated ionotropic P2X7 receptor controls follicular T helper cell numbers in Peyer’s patches to promote host-microbital mutualism. *Immunity* (2014) 41:789–801. doi:10.1016/j.immuni.2014.10.010

68. Praetorius HA, Leipziger J. ATP release from non-excitatory cells. *Purinergic Signal* (2009) 5:433–46. doi:10.1007/s11232-009-9146-2

69. Loomis WH, Namiki S, Ostrom RS, Insel PA, Junger WG. Hypertonic stress increases T cell interleukin-2 expression through a mechanism that involves ATP release, P2 receptor, and p38 MAPK activation. *J Biol Chem* (2003) 278:4590–6. doi:10.1074/jbc.M207868200

70. Woehre T, Yip L, Manohar M, Sumi Y, Yao Y, Chen Y, et al. Hypertonic stress regulates T cell function via pannexin-1 hemichannels and P2X7 receptors. *J Leukoc Biol* (2010) 88:1181–9. doi:10.1189/jlb.0410211

71. Schenk U, Westendorf AM, Radalle F, Casati A, Ferro M, Fumagalli M, et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. *Sci Signal* (2008) 1:r6–6. doi:10.1126/scisignal.1160583

72. Yip L, Woehre T, Corriden R, Hirsh M, Chen Y, Inoue Y, et al. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. *FASEB J* (2009) 23:1685–93. doi:10.1096/fj.08–126458

73. Sarukhan A, Garcia C, Lanoue A, Boehmer von H. Allergic inclusion of T cell receptor alpha genes poses an autoimmune hazard due to low-level expression of autospecific receptors. *Immunity* (1998) 8:563–70. doi:10.1016/S1074-7613(00)00561-0

74. Trabanelli S, Očadlíková D, Gulinelli S, Curti A, Salvestrini V, Vieira RP, et al. Connexin-43 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. *Blood* (2010) 116:3475–84. doi:10.1182/blood-2010-04-277707

75. Rissiek B, Koch-Nolte F, Magnus T. Nanobodies as modulators of inflammation: potential applications for acute brain injury. *Front Cell Neurosci* (2014) 8:344. doi:10.3389/fncel.2014.00344

76. Adinolfi E, Pizzirani C, Iđžko M, Panther E, Norgauer J, Virgilio F, et al. P2X7 receptor: death or life? *J Immunol* (2005) 174:121–7. doi:10.1074/jimmunol.056603

77. Trabanelli S, Očadlíková D, Gulinelli S, Curti A, Salvestrini V, Vieira RP, et al. Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation. *J Immunol* (2012) 189:1303–10. doi:10.4049/jimmunol.1103800

78. Baricordi OR, Ferrari D, Melchiorri L, Chiozzi P, Hanau S, Chiari E, et al. An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. *Blood* (1996) 87:682–90.

79. Burnstock G, Boenens J-M. Purinergic signalling and immune cells. *Purinergic Signal* (2014) 10:529–64. doi:10.1007/s11232-014-9427-2

80. Junger WG. Immune cell regulation by autocrine purinergic signalling. *Nat Rev Immunol* (2011) 11:201–2. doi:10.1038/nri2938

Conflict of Interest Statement: Friedrich Koch-Nolte and Friedrich Haag receive royalties from sales of antibodies developed in the lab via MediGate GmbH, a 100% subsidiary of the University Medical Center, Hamburg. The other co-authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Rissiek, Haag, Boyer, Koch-Nolte and Adiouch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.